Panacea Biotec (PANACEABIO)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At its core, this is not a business I would back without a clear path to sustained profitability. Panacea Biotec sells at ₹356.50, a market cap of ₹2,027 crore, while book value is only ₹51.56. That means I am asked to pay 6.9 times book for a business that earned a return on equity of -13.29% and a return on capital of -4.57%. Graham wouldn't focus on the growth story; he would focus on whether the company earns more than its cost of capital. Right now it does not. The trailing P/E is effectively zero because earnings are absent. The latest quarter's net profit of ₹4 crore on sales of ₹165 crore is a sign of life, but the margin is far too thin to justify this valuation. Sales growth is flat at just over 1%, so the 32% profit growth is coming off a small base, not from a robust expanding franchise. There are some positives: debt/equity is only 0.03, and promoter holding is high at 72.48%, so shareholders and management are aligned. The Piotroski score of 6/9 hints at improving fundamentals, but it is not a moat. No dividend means minority shareholders rely entirely on capital appreciation, and for that, Panacea must improve ROE materially. A genuine turnaround can be worth a lot as an option; but at ₹356.50 the market is already pricing in success that I cannot verify. This is a turnaround candidate, not a compounder. I need to see at least several quarters of real earnings, positive ROE, and revenue growth before I can apply a Graham-style margin of safety.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer